Achilles Therapeutics ( (ACHL) ) just unveiled an update.
Achilles Therapeutics has announced a proposal for a members’ voluntary liquidation to return capital to shareholders following a strategic review and asset sale. This decision follows the transfer of its TRACERx license and materials to AstraZeneca for $12 million, marking the end of its strategic review process, with the General Meeting scheduled for March 20, 2025, to discuss the liquidation.
More about Achilles Therapeutics
Achilles Therapeutics is a biotechnology company focused on developing T cell therapies and tumor-infiltrating lymphocytes (TILs) for the treatment of cancer. The company has been involved in creating personalized cancer treatments through its innovative approaches in the biotechnology sector.
YTD Price Performance: -0.88%
Average Trading Volume: 177,449
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $46.44M
For a thorough assessment of ACHL stock, go to TipRanks’ Stock Analysis page.